$GH

CLARK IAN T sold $2.3M of GH (indirect holdings)

CLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.

Original reporting
SEC EDGAR · CLARK IAN T
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 14,180 shares (about $2.25M) at roughly $158.8 to $159.0 per share, with holdings after the sale of 2,975 shares.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it does not introduce new company fundamentals or guidance.

03

What to watch

No 10b5-1 plan is disclosed here, but the article also provides no context on total holdings, prior sale cadence, or whether other insiders are buying or selling around the same period.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, trades dated 2026-08-04

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Clark Ian T sold $2.25M of GH shares via two open-market trades at about $158.9 on 2026-08-04.

Expected impact

Limited near-term impact; any effect is likely transient unless followed by additional insider selling or new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a moderate dollar value, but it does not include new operational, financial, or regulatory information.

Market effects

Minimal; insider selling at one healthcare diagnostics name does not materially change sector expectations.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity needs rather than a view on business prospects, especially given the lack of a stated fundamental catalyst in the filing.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an insider director via open-market transactions.

  • CLARK IAN T

    Director who sold 14,180 shares of GH on 2026-08-04, reported on 2026-08-05.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.

$GHMedAI 8/10

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

Diagnostics company Guardant Health (NASDAQ: GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates. Is now the time to buy Guardant Health? Find out by accessing our full research report, it’s free.